Marksans Pharma informs about press release
Marksans Pharma has informed that it enclosed press release regarding the final approval of the Company’s Abbreviated New Drug Application (ANDA) for Benzonatate Capsules USP, 100 mg & 200 mg (Rx) from USFDA. This product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Tessalon Capsules, 100 mg and 200 mg, of Pfizer Inc. Benzonatate is a non-narcotic antitussive that numbs stretch receptors in the respiratory tract, reducing the cough reflex and relieving persistent cough, bronchitis, pneumonia or other lung infections.
The above information is a part of company’s filings submitted to BSE.
